Pharmacopsychiatry 2005; 38(2): 102-104
DOI: 10.1055/s-2005-837813
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Depression during Therapy with Interferon α - How Long Should an Antidepressant Treatment Last?

A Case ReportT. Nickel1 , A. Sonntag1 , M. Backmund2 , T. Pollmächer1
  • 1Max Planck Institute of Psychiatry, Munich, Germany
  • 2Department of Internal Medicine, General Hospital Munich, Munich, Germany
Further Information

Publication History

Received: 13.3.2004 Revised: 6.7.2004

Accepted: 27.7.2004

Publication Date:
02 March 2005 (online)

Although depressive symptoms are well-known side effects of interferon alpha (IFNα), it is uncertain if these symptoms decline with the cessation of IFNα therapy. We report on a 47-year-old man who, apart from former drug abuse, never had suffered from a psychiatric disorder. However, he had a family history burdened with the suicide of his mother and his twin sister. After a depressive symptomatology during the IFNα therapy, which had been tolerably treated by mirtazapine, he committed a suicide attempt six months after the parallel termination of IFNα and antidepressant treatment. Two aspects of this case report should be emphasised. First, patients with an increased risk for psychiatric complications of interferon therapy must be followed closely for a depressive symptomatology and treated aggressively if symptoms arise. Second, this case report shows the relapse of depressive symptoms far beyond the end of the interferon treatment. If an antidepressant treatment is necessary during IFNα therapy this should not be stopped prematurely with the termination of the interferon medication.

References

  • 1 Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C, Clemens J. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C.  Psychosomatics. 2001;  42 365-367
  • 2 Dieperink E, Ho S B, Thuras P, Willenbring M L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.  Psychosomatics. 2003;  44 104-112
  • 3 Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.  J Hepatol. 1996;  24 38-47
  • 4 Fukunishi K, Tanaka H, Maruyama J, Takahashi H, Kitagishi H, Ueshima T ,. et al . Burns in a suicide attempt related to psychiatric side effects of interferon.  Burns. 1998;  24 581-583
  • 5 Gohier B, Goeb J L, Rannou-Dubas K, Fouchard I, Cales P, Garre J B. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients.  World J Biol Psychiatry. 2003;  4 115-118
  • 6 Janssen H LA, Brouwer J T, van der Mast R C, Schalm S W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis.  J Hepatol. 1994;  21 241-243
  • 7 Kraus M R, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa.  N Engl J Med. 2001;  345 375-376
  • 8 Musselman D L, Lawson D H, Gumnick J F, Manatunga A K, Penna S, Goodkin R S,. et al . Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 961-966
  • 9 Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre J B,. et al . Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha.  Gastroenterol Clin Biol. 1998;  22 353-357
  • 10 Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N ,. et al . Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.  Hepatology. 2003;  37 443-451
  • 11 Williams C D, Linch D C. Interferon alfa-2a.  Br J Hosp Med. 1997;  57 436-439

Dr. Thomas Nickel

Max Planck Institute of Psychiatry

Kraepelinstr. 10

80804 Munich

Germany

Phone: +49 89 30622 420

Fax: +49 89 30622 605

Email: nickel@mpipsykl.mpg.de

    >